A 58-year-old man with metastatic pancreatic cancer presents to the palliative care unit with severe pain (8/10). He has been on paracetamol 1 g QID and ibuprofen 400 mg TDS without adequate relief. His vital signs are stable: BP 128/82 mmHg, HR 88/min, RR 16/min, SpO₂ 98% on room air. Liver function tests are mildly deranged (bilirubin 2.8 mg/dL, AST 52 U/L). Renal function is normal (creatinine 0.9 mg/dL). The palliative care physician decides to initiate opioid therapy. Which of the following opioids is MOST appropriate as the first-line agent for this patient?

Explanation

## Opioid Selection in Cancer Pain Management ### Initial Opioid Choice Rationale **Key Point:** Morphine immediate-release (IR) formulation is the WHO-recommended first-line opioid for moderate-to-severe cancer pain in opioid-naïve patients. **High-Yield:** The WHO analgesic ladder (Step 3) mandates: 1. Start with **morphine IR** (short-acting) for titration 2. Titrate dose every 24–48 hours until pain control achieved 3. Once stable dose identified, switch to extended-release (ER) formulation for convenience ### Why Morphine IR Is Optimal Here | Feature | Morphine IR | Methadone | Fentanyl TD | Codeine | |---------|-----------|----------|-----------|----------| | **Onset** | 30–60 min | 6–12 hrs | 12–24 hrs | 30–60 min | | **Titration** | Easy, rapid | Difficult, long half-life | Not suitable for titration | Weak opioid | | **Opioid-naïve** | First-line | Avoided (complex PK) | Contraindicated | Inadequate potency | | **Liver disease** | Caution, but manageable | Avoid (hepatic metabolism) | Acceptable | Weak | | **Reversibility** | Naloxone effective | Prolonged antagonism needed | Prolonged reversal | Naloxone effective | **Clinical Pearl:** This patient has mild hepatic impairment (bilirubin 2.8, AST 52), which is NOT a contraindication to morphine IR. Morphine undergoes hepatic glucuronidation; mild liver disease does not significantly impair this. However, methadone (extensively hepatically metabolized) and fentanyl (hepatic metabolism) carry higher risk of accumulation. ### Titration Strategy 1. **Initial dose:** Morphine IR 5–10 mg every 4 hours 2. **Breakthrough pain:** Same dose as regular dose, given as needed 3. **Escalation:** Increase by 25–50% every 24–48 hours based on pain control and side effects 4. **Once stable:** Convert to ER formulation (e.g., morphine ER 12-hourly or 24-hourly) using total daily morphine requirement **Mnemonic:** **TRAM** — Titrate, Reassess, Adjust, Monitor **Key Point:** Renal function is normal (creatinine 0.9), so morphine-6-glucuronide (active metabolite) will not accumulate. ## Why Other Options Are Suboptimal ### Methadone - **Problem:** Extremely long and unpredictable half-life (15–60 hours); difficult to titrate in opioid-naïve patients - **Risk:** Accumulation with repeated dosing → overdose, respiratory depression - **Reserved for:** Opioid-tolerant patients with neuropathic pain or opioid-induced side effects refractory to other agents ### Fentanyl Transdermal - **Problem:** Designed for opioid-tolerant patients only; NOT suitable for opioid-naïve individuals - **Reason:** Cannot be titrated rapidly; 12–24 hours to reach steady state; no way to reduce dose quickly if toxicity develops - **Risk:** Severe respiratory depression, death in opioid-naïve patients - **Indication:** Reserved for patients already on stable opioid doses (e.g., converting from morphine ER) ### Codeine - **Problem:** Weak opioid (Step 2 analgesic ladder); inadequate for severe cancer pain - **Limitation:** Ceiling effect at 240 mg/day; requires hepatic metabolism to morphine (prodrug) - **Indication:** Mild-to-moderate pain only; this patient has 8/10 pain requiring Step 3 opioid ## Safety Considerations **Warning:** Monitor for opioid-induced side effects: - Constipation (almost universal; start laxative prophylaxis) - Nausea (often transient; consider antiemetic) - Drowsiness (usually resolves with titration) - Respiratory depression (less likely with slow titration in opioid-naïve patients) **Clinical Pearl:** Always prescribe a breakthrough pain dose (same as regular dose) and counsel patient on when to use it. This allows rapid pain control between dose escalations.